Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

6.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
Pigmentation01:19

Pigmentation

5.0K
The color of the skin is influenced by a number of pigments, including melanin, carotene, and hemoglobin. Recall that melanin is produced by cells called melanocytes, which are found scattered throughout the stratum basale of the epidermis. The melanin is transferred to the keratinocytes via melanosomes.
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
1.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.4K
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Chemotherapy in combination with KRAS inhibitors in <i>KRAS</i>-mutated non-small cell lung cancer.

Journal of thoracic disease·2026
Same author

Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS <sup>G12C</sup> NSCLC.

Scientific reports·2026
Same author

Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy.

Cancer immunology, immunotherapy : CII·2026
Same author

Fulzerasib plus cetuximab in first-line KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.

The Lancet. Oncology·2026

Related Experiment Video

Updated: Mar 31, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K

Focused issue on "Melanoma"

María González-Cao

    Annals of Translational Medicine
    |October 22, 2015
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
    06:09

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

    Published on: June 7, 2019

    9.7K
    A Melanoma Patient-Derived Xenograft Model
    07:07

    A Melanoma Patient-Derived Xenograft Model

    Published on: May 20, 2019

    13.4K

    Related Experiment Videos

    Last Updated: Mar 31, 2026

    A 3D Organotypic Melanoma Spheroid Skin Model
    08:49

    A 3D Organotypic Melanoma Spheroid Skin Model

    Published on: May 18, 2018

    16.8K
    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
    06:09

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

    Published on: June 7, 2019

    9.7K
    A Melanoma Patient-Derived Xenograft Model
    07:07

    A Melanoma Patient-Derived Xenograft Model

    Published on: May 20, 2019

    13.4K